Cost-Effectiveness of Technology-Assisted Case Management in Low-Income, Rural Adults with Type 2 Diabetes
Bibliographic Data
| ID | 19578499 |
|---|---|
| Authors | L E Egede (0000-0003-1546-1515, Medical College of Wisconsin, corresponding author), Clara E Dismuke (VA Palo Alto Health Care System), Rebekah J Walker (0000-0002-7773-557X, Medical College of Wisconsin), Joni S Williams (0000-0001-8988-3556, Medical College of Wisconsin), Christian Eiler (Medical College of Wisconsin) |
| Year | 2021 |
| Volume | 5 |
| Issue | 1 |
| Pages | 503-511 |
| Publication date | 2021-07-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Health Equity (JOURNAL) |
| Journal identifiers | ISSN: 2473-1242 • E-ISSN: 2473-1242 |
| Publisher | SAGE Publications (PUBLISHER • US) |
| DOI | 10.1089/heq.2020.0134 |
| PMID | 34327293 |
| OpenAlex | W3185994016 |
| Language | EN |
| References cited | 44 |
Objective: The objective of this study was to examine whether delivering technology-assisted case management (TACM) with medication titration by nurses under physician supervision is cost effective compared with usual care (standard office procedures) in low-income rural adults with type 2 diabetes. Methods: One hundred and thirteen low-income, rural adults with type 2 diabetes and hemoglobin A1c (HbA1c) ≥8%, were randomized to a TACM intervention or usual care. Effectiveness was measured as differences in HbA1c between the TACM and usual care groups at 6 months. Total cost per patient included intervention or usual care cost, medical care cost, and income loss associated with lost workdays. The total cost per patient and HbA1c were used to estimate a joint distribution of incremental cost and incremental effect of TACM compared with usual care. Incremental cost-effectiveness ratios (ICERs) were estimated to summarize the cost-effectiveness of the TACM intervention relative to usual care to decrease HbA1c by 1%. Results: Costs due to intervention, primary care, other health care, emergency room visits, and workdays missed showed statistically significant differences between the groups (usual care $1,360.49 vs. TACM $5,379.60, p=0.004), with an absolute cost difference of $4,019.11. Based on the intervention cost per patient and the change in HbA1c, the median bootstrapped ICERs was estimated to be $6,299.04 (standard error=731.71) per 1% decrease in HbA1c. Conclusion: Based on these results, a 1% decrease in HbA1c can be obtained with the TACM intervention at an approximate cost of $6,300; therefore, it is a cost-effective option for treating vulnerable populations of adults with type 2 diabetes
Cost effectiveness · Diabetes management · Diabetes mellitus · Health care · Randomized controlled trial · Type 2 diabetes · Chronic Disease Management Strategies · Diabetes Management and Education · Diabetes Management and Research · Medicine · Nursing · Emergency Medicine · Internal Medicine
| Highly cited | No |
|---|